Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3446466 | 0.95 | NR1H4 (0.83) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3445294 | 0.94 | NR1H4 (0.84) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3445257 | 0.93 | NR1H4 (0.88) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3444909 | 0.92 | NR1H4 (1.00) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3445999 | 0.91 | NR1H4 (0.85) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3447059 | 0.90 | NR1H4 (0.72) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3446664 | 0.90 | NR1H4 (0.78) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3446118 | 0.89 | NR1H4 (0.83) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3446324 | 0.88 | NR1H4 (0.84) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 | |
| SCHEMBL3444741 | 0.87 | NR1H4 (1.00) | NR1H4CYP2C9KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816540-B2 | Carboxyl- or hydroxyl-substituted benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2225221-A2 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009080555-A2 | CARBOXYL- OR HYDROXYL- SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885CYP2C9 79/4885KCNH2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.